<DOC>
	<DOC>NCT00475605</DOC>
	<brief_summary>This is an observational study to assess the long-term safety of Protopic® Ointment for the treatment of atopic dermatitis. Patients whose ages are/were &lt; 16 years at the time of first tacrolimus ointment exposure are eligible to participate. No drug is distributed during this observational trial.</brief_summary>
	<brief_title>A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis</brief_title>
	<detailed_description>Data will be collected at enrollment and every 6 months thereafter either by interview, Internet, or physician office visit. Each subject will be followed for 10 years in this study.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Subjects who first used Protopic® 0.03% or 0.1% before they were sixteen years of age and were treated for at least 6 weeks for the treatment of Atopic dermatitis may enroll into the study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>atopic dermatitis</keyword>
	<keyword>child</keyword>
	<keyword>tacrolimus ointment</keyword>
	<keyword>Protopic Ointment</keyword>
</DOC>